Phase III Study Results on the Efficacy and Safety of Canakinumab, a Long-Acting, Fully Human Anti-Interleukin-1 beta Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features.
ARTHRITIS AND RHEUMATISM（2011）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要